The Effects of Foods on Blood Lipids in Non-alcoholic Fatty Liver Disease (NAFLD)—A Systematic Review and Meta-Analysis

Fredrik Rosqvist¹, Andreas Rydell²,³ and David Iggman¹,²*¹

¹ Clinical Nutrition and Metabolism, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden,
² Norslund-Svärdsjö Academic Health Care Center, Center for Clinical Research Dalarna, Falun, Sweden,
³ Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institute, Huddinge, Sweden

**Background:** Non-alcoholic fatty liver disease (NAFLD) is associated with dyslipidemia and increased cardiovascular disease risk. Dietary choices may produce profound effects on blood lipids. Thus, the purpose of this study was to investigate which foods modify blood lipids in NAFLD.

**Methods:** Systematic review of published systematic reviews and randomized controlled trials (RCTs). Searches were performed in PubMed, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials, from inception through March 2020. Studies in populations with NAFLD, which provided data on foods or dietary patterns and blood lipids were included, but not weight loss diets, supplements, nor individual nutrients. The strength of evidence was evaluated using The Grading of Recommendations Assessment, Development, and Evaluation (GRADE).

**Results:** No relevant systematic reviews were identified. Eleven RCTs were included in the qualitative synthesis. Two RCTs were included in meta-analyses, regarding the comparison between Mediterranean and Low-fat diets, in which there were no clear effects on either high-density lipoprotein cholesterol or triglycerides, with Low evidence. From single RCTs, there was Moderate evidence for reduced triglycerides by a healthy dietary pattern, compared with usual care; and for reduced total cholesterol by a probiotic yogurt, enriched with *Lactobacillus acidophilus* La5 and *Bifidobacterium lactis* Bb12, compared with conventional yogurt. For all other comparisons, the evidence was considered as Low or Very low.

**Conclusion:** Few studies were identified which reported effects of foods on blood lipids in subjects with NAFLD. The possible beneficial effect of probiotics warrants further study.

**PROSPERO identifier:** CRD42020178927.

**Keywords:** NAFLD, steatosis, cholesterol, triglycerides, diet, food
INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is a prevalent and emerging public health concern, closely associated with obesity, metabolic syndrome, insulin resistance, and type 2 diabetes (1). Individuals with NAFLD frequently present with dyslipidemia, typically elevated fasting plasma triglycerides and/or low high-density lipoprotein (HDL) cholesterol, but not necessarily elevated low-density lipoprotein (LDL) cholesterol (2); and may have high, or even very high, cardiovascular disease (CVD) risk (3). Dietary choices may produce profound and rapid effects on plasma lipoproteins, even under isocaloric conditions, and is thus possible to determine with high evidence in well-conducted short-term randomized controlled trials (RCTs). When several foods with cholesterol-lowering effects are combined (e.g., in the Portfolio diet) in strictly controlled settings, effects approaching 30% may be achieved on the group level (4). However, the effects of dietary fat quality (e.g., saturated and polyunsaturated fat) on LDL cholesterol and levels of apolipoprotein B are less pronounced in individuals with obesity than without (5). Considering the strong association between NAFLD and obesity, it can thus be speculated that the effect of dietary fat type may be less effective in individuals with compared to without NAFLD (due to concomitant overweight), however this requires further investigation. Factors proposed to blunt the effectiveness of dietary fat modification on LDL cholesterol in obesity (and thus speculatively in NAFLD) are increased inflammation, insulin resistance and endogenous cholesterol synthesis (6). Triglycerides may also be causally associated with CVD risk and can be clearly affected by diet and/or weight loss, although by distinctly different food choices than regarding hypercholesterolemia (7). The mechanisms through which foods influence plasma lipoproteins are partly unknown and may also be independent of the overall dietary fatty acid composition (8). The main routes involve intestinal absorption and excretion of lipids (including bile acids), or hepatic synthesis or clearance from the circulation. However, it is unknown whether hepatic steatosis modifies these effects. For instance, foods affecting gut microbiota (e.g., probiotics and prebiotics) may be of special importance. Also, foods affecting intestinal cholesterol uptake (e.g., foods enriched with phytosterols and/or stanols) could theoretically have less importance in NAFLD compared with foods believed to mainly exert direct effects on the liver, e.g., foods rich in polyunsaturated fatty acids (PUFA). Thus, we aimed to systematically evaluate the literature for the effects of foods on blood lipids in persons with NAFLD.

METHODS

A systematic search for systematic reviews and RCTs was performed, in PubMed, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials, from inception through March 2020. The PICO and full search strategy are provided in Table 1. Included search terms were selected based on dyslipidemia guidelines and studies in other populations. The target population was adults with

TABLE 1 | PICO and search strategy.

| Population: Adults with NAFLD, not taking lipid-lowering medication |
| Control: Background diet or comparison foods, but not lower dose of the same food |
| Interventions: Intake of foods and dietary patterns, but not weight loss diets, supplements, or non-individual nutrients |
| Outcomes: Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, apo B, apo AI, non-HDL cholesterol, other lipoproteins and subfractions, oxidized LDL cholesterol |

Searches in PubMed, Cochrane database of systematic reviews and cochrane central register of controlled trials, through March 2020

Filter: RCTs, systematic reviews and meta-analyses. Modified for Pubmed by: systematic review[tiab] OR systematic literature review[tiab] OR systematic mapping review[tiab] OR systematic narrative review[tiab] OR systematic qualitative review[tiab] OR systematic evidence review[tiab] OR systematic quantitative review[tiab] OR systematic meta-review[tiab] OR systematic critical review[tiab] OR systematic mixed studies review[tiab] OR systematic mapping review[tiab] OR systematic cochrane review[tiab] OR systematic search and review[tiab] OR systematic integrative review[tiab] OR systematic review[pt] OR randomized controlled trial[pt] OR randomized[tiab] AND controlled[tiab] AND trial[tiab] OR meta-analysis[tiab] OR meta-analysis[pt] OR Meta-Analysis[pt] OR meta-analysis[tiab] OR Meta-Analysis[pt]

Title/Abstract: Lipidemia* OR Dyslipidemia* OR Hyperlipidemia* OR Cholesterol* OR Lipoprotein* OR MeSH Terms: Dyslipidemias OR Hyperlipidemias OR Cholesterol OR “Cholesterol, LDL” OR Lipoproteins AND

Title/Abstract: Food OR Foods OR Diet OR Diets OR Dietary OR Coffee OR Butter OR Oil OR Saturated fat* OR Unsaturated fat* OR Monounsaturated fat* OR Polyunsaturated fat* OR Fish OR Soluble fiber* OR Viscous fiber* OR soluble fiber* OR viscous fiber* OR Oats OR Barley OR Psyllium OR Flaxseeds OR Soy OR Almonds OR Nuts OR Plant sterol* OR Plant stanol* OR Phytosterol* OR Phytosteroid* OR Tomato OR Sugar OR Carbohydrate* OR Alcohol OR Omega-3 OR MeSH terms: Food OR Diet OR Coffee OR Butter OR “Plant Oils” OR “Fatty Oils” OR “Fatty Acids, Unsaturated” OR “Fatty Acids, Monounsaturated” OR “Fatty Acids, Omega-3” OR “Fish Products” OR “Fish Oils” OR Avena OR Hordeum OR “Edible Grain” OR Psyllium OR Flax OR “Soy Foods” OR “Prunus dulcis” OR Nuts OR Phytosterols OR “Lycopersicon esculentum” OR Sugars OR Carbohydrates OR Alcohols AND

Title/Abstract: NAFLD OR “Fatty liver” OR “Liver steatosis” OR MeSH terms: “Non-alcoholic Fatty Liver Disease”

apo, apolipoprotein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAFLD, non-alcoholic fatty liver disease; MUFA, monounsaturated fatty acids; RCT, randomized controlled trial; "Wildcard character.
NAFLD, not taking lipid-lowering medication. In order to be included, studies must include information on NAFLD diagnosis or provide other data of liver fat content of participants, and a clear majority of participants must conform with inclusion criteria. Interventions of interest were foods and dietary patterns, but not single nutrients (not clearly associated with specific foods), supplements, nor weight loss diets. As comparison, other foods or background diets were acceptable, but not different doses of the same food. The outcomes of interest were LDL cholesterol, total cholesterol, HDL cholesterol, apolipoprotein B, apolipoprotein A1, triglycerides, non-HDL cholesterol, oxidized LDL cholesterol, and other lipoproteins and subfractions. If data was not reported, authors were not contacted for additional information, however, for included studies, if data was ambiguous, authors were contacted for clarification. Bibliographies of included RCTs were screened for additional studies. Language was restricted to English. The study protocol is available at www.crd.york.ac.uk/PROSPERO, identifier CRD42018089661. No ethics approval was required.

STUDY SELECTION, DATA EXTRACTION, RISK OF BIAS, AND EVIDENCE ASSESSMENTS

Two reviewers screened abstracts and in cases of disagreement, the paper was included for full-text review. From RCTs that fulfilled inclusion criteria, data was extracted by at least two researchers using standardized forms including: author, year, study type (parallel/crossover), population (NAFLD/other), n analyzed overall and per group, % male, age in years (mean ± SD and/or range), intervention/daily dose (mean ± SD and/or range), control/daily dose (mean ± SD and/or range), effects on lipids (mean difference, 95%CI and/or mean) for intervention and control groups), duration, country, and funding. Risk of bias in RCTs was assessed by two authors using the SBU Risk of Bias tool for intervention studies (version 6 May 2020). The quality of evidence was evaluated using The Grading of Recommendations Assessment, Development, and Evaluation (GRADE), by pre-determined criteria for risk of bias, inconsistency, indirectness, imprecision, publication bias, large effects, dose response relationships, and opposing bias. For instance, evidence was downgraded (-1) for inconsistency if results were not replicated, as consistent results of low heterogeneity are impossible to attain from a single RCT. In indeterminate cases, discussions were extended among all authors and overall judgments were employed.

DATA SYNTHESIS AND ANALYSIS

Results from included RCTs were included in meta-analyses, when considered appropriate, using ReviewManager 5.3 software. The Cochrane Handbook (9) was adhered to. In cases of at least moderate (I²>50%) unexplained heterogeneity, random effects models were preferred. If mean changes from baseline and their standard deviations were unavailable and impossible to calculate, end-of-study means and standard deviations were used. Cross-over studies were included together with parallel studies, with modified weights, calculated from available data. In cases where the variances of mean differences were unavailable, a conservative correlation R = 0.5 was imputed and standard deviations adjusted accordingly. Mg/dL was converted to mmol/L by multiplication with 0.02586 for cholesterol and 0.01129 for triglycerides. Data is presented as mean±SD. P-values > 0.05 were considered as non-significant (NS).

RESULTS

Six systematic reviews and 26 RCTs were evaluated in full text. No systematic reviews and 11 RCTs (12 publications) fulfilled inclusion criteria (Figure 1). The characteristics of the 11 included RCTs are presented in Table 2. The excluded papers are presented, with reasons, in Table 3. The overall risk of bias was considered as Low in three RCTs, Some concerns in six RCTs, and High in two RCTs (Table 2 and Figure 2). Four RCTs compared dietary patterns and the remaining seven compared food items. The overall results on blood lipids and the evidence gradings for each available outcome are presented in Table 4. Two studies were considered appropriate to include in meta-analyses, as they both compared a Mediterranean with a Low-fat dietary pattern (Figure 3).

DIETARY PATTERNS

Healthy Dietary Pattern vs. Usual Care

In the RCT by Arab et al. (10), there were significant reductions in both total cholesterol (from 5.56 ± 1.6 to 5.01 ± 1.8 mmol/l in intervention vs. from 4.81 ± 0.92 to 4.91 ± 0.89 mmol/l in control group, P = 0.04) and triglycerides (from 2.46 ± 1.9 to 1.86 ± 0.98 vs. from 2.11 ± 1.7 to 2.21 ± 1.4 mmol/L, P = 0.002). There was a tendency toward reduced LDL cholesterol (from 3.11 ± 1.0 to 2.83 ± 1.1 vs. from 2.87 ± 0.84 to 2.96 ± 0.79 mmol/L, P = 0.46), but no clear effect for HDL cholesterol (from 1.20 ± 0.29 to 1.16 ± 0.20 vs. from 1.12 ± 0.26 to 1.07 ± 0.20 mmol/L, P = 0.12). The quality of evidence for the effect on triglycerides was considered as Moderate, upgraded for large effects, whereas all other comparisons were further downgraded to Very low evidence, due to high imprecision.

Mediterranean Diet vs. Low-Fat Diet

From the RCTs by Properzi et al. (19) and Ryan et al. (20), effects on HDL cholesterol and triglycerides were combined in meta-analyses, but there were no clear effects (Figure 3). Effects on total and LDL cholesterol were only reported in the study by Properzi et al. (19), with an indicated slight reduction for total cholesterol (from 4.78 ± 1.3 to 4.53 ± 1.3 vs. from 5.23 ± 0.90 to 5.15 ± 1.1 mmol/L, NS), but no meaningful effect on LDL cholesterol (from 2.83 ± 1.2 to 2.73 ± 1.1 vs. from 3.20 ± 0.78 to 3.17 ± 0.86 mmol/L, NS). The evidence was considered as Low for all outcomes.
High-Monounsaturated Fatty Acid Diet vs. High-Carbohydrate, High-Fiber, Low-Glycemic Index Diet

In the RCT by Bozetto et al. (12, 13), there were tendencies (all NS) toward reductions after the high-monounsaturated fatty acid (MUFA) diet vs. high-carbohydrate (high-CHO) diet, for total (from 4.32 ± 0.65 to 4.29 ± 0.59 vs. from 4.06 ± 0.98 to 4.24 ± 1.2 mmol/L) and LDL cholesterol (from 2.85 ± 0.52 to 2.82 ± 0.54 vs. from 2.53 ± 0.75 to 2.77 ± 1.0 mmol/L), and for triglycerides (from 1.38 ± 0.42 to 1.29 ± 0.37 vs. from 1.24 ± 0.77 to 1.48 ± 1.2 mmol/L). There was no clear effect on HDL cholesterol (from 0.91 ± 0.2 to 0.93 ± 0.1 vs. from 0.96 ± 0.2 to 0.96 ± 0.2 mmol/L). The evidence was considered as Very low. In the report from 2014 (10), results were reported on postprandial lipids combined with 19 (8 + 11 per group) additional subjects that were also prescribed exercise training. Post-prandial (after 2, 4, and 6 h, presented as figure) triglycerides and cholesterol in plasma and chylomicrons/very-low-density lipoproteins were increased after the MUFA diet (P < 0.05) and reduced after the high-CHO diet (P < 0.05). We did not perform evidence gradings for these outcomes, as they were not clearly pre-specified.

FOODS

Artificially vs. Sugar-Sweetened Beverages

In the RCT by Campos et al. (14), triglycerides tended to increase by artificially (from 1.35 ± 0.2 to 1.5 ± 0.3 mmol/L) vs. sugar-sweetened beverages (from 2.0 ± 0.6 to 1.3 ± 0.2 mmol/L), however based on only 8+7 individuals with steatosis, and the
| References | Design | Intervention, daily dose | Comparison, daily dose | Duration | Country | Funding | Risk of bias |
|-----------|--------|--------------------------|------------------------|----------|---------|---------|-------------|
| Arab et al. (10) | Parallel | n = 69 (36 + 33), 32% males | Healthy dietary pattern (fruit, vegetables, complex carbohydrates, low fat dairy, healthy fats, white meat, and fish; avoid unhealthy fats and refined carbohydrates) | Usual care (reduce calories, carbohydrates, and fat) | 2 months | Iran | Isfahan University | Some concerns |
| Bakhshimoghaddam et al. (11) | Parallel | n = 102 (34 + 34 + 34), 49% males | 300 g synbiotic yogurt (B. animalis and inulin) + advice on healthy lifestyle | 300 g conventional yogurt (Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus) + advice on healthy lifestyle; or advice on healthy lifestyle only | 24 weeks | Iran | Urmia University | Some concerns |
| Bozzetto et al. (12, 13) | Parallel | n = 17 (8 + 9), 76% males | MUFA diet with olive oil, fat 42%E (MUFA 27E%, SFA 6.7E%, PUFA 4.8E%), CHO 40E% | CHO/fiber/Low-GI diet: fat 28E% (MUFA 16E%, SFA 6E%, PUFA 3.8E%), CHO 53E% | 8 weeks | Italy | EU funding, Italian diabetes society | Some concerns |
| Campos et al. (14) | Parallel | n = 15 (8 + 7), 52% males | Artificially sweetened beverages, at least 660 ml (replacing habitual consumption of sugar-sweetened beverages) | Sugar-sweetened beverages, continue with habitual intake of at least 660 ml | 12 weeks | Switzerland | Swiss national foundation for science, Fondation Raymond Berger pour la recherche sur le diabete et les maladies metaboliques | High risk |
| Dinu et al. (15) | Parallel | n = 40 (20 + 20), 30% males | Kamut khorasan wheat, 71 g pasta, 21 g bread, 36 g crackers, 36 g biscuits | Modern wheat, 71 g pasta, 21 g bread, 36 g crackers, 36 g biscuits | 3 months | Italy | Kamut enterprises of Europé | Some concerns |
| Khavasi et al. (16) | Parallel | n = 44 (22 + 22), 34% males | Pickled caper fruit, 40–50 gram + lifestyle changes | Lifestyle changes only | 12 weeks | Iran | Tabriz University | High risk |
| Nabavi et al. (17) | Parallel | n = 72 (36 + 36), 49% males | Probiotic yogurt (L. acidophilus La5 and B. lactis Bb12 + Lactobacillus bulgaricus and Streptococcus thermophilus), 300 g | Conventional yogurt (L. bulgaricus and Streptococcus thermophilus), 300 g | 8 weeks | Iran | Tabriz University | Low risk |
| Nigam et al. (18) | Parallel | n = 93 (30 + 33 + 30), 100% males | Olive oil, 20 g | Canola oil, 20 g or commonly used oil (soybean or safflower), 20 g | 6 months | India | Dalmia Continental Pvt. Ltd. | Some concerns |
| Properzi et al. (19) | Parallel | n = 48 (24 + 24), 52% males | Mediterranean diet + 27 g nuts (almonds or walnuts) and 27 mL olive oil | Low-fat diet + 36 g natural muesli and 7 g low-fat snack bar | 12 weeks | Australia | Australian government research training program scholarship | Low risk |
| Ryan et al. (20) | Crossover | n = 12, 50% males | Cretan Mediterranean diet 40/40/20%E fat/CHO/protein (ad libitum, food supplied) | Low-fat-high carbohydrate diet 30/50/20%E fat/CHO/protein (ad libitum, food supplied) | 6 weeks | Australia | NHMRC Neil Hamilton Fairley Fellowship/University of Melbourne | Low risk |
| Sofi et al. (15) | Parallel | n = 11 (6 + 5), 82% males | Olive oil enriched with n-3 PUFA, 6.5 ml (0.83 g n-3 PUFA, of which 0.47 g EPA and 0.24 g DHA, supplied) | Olive oil, 6.5 ml (supplied) | 12 months | Italy | N/A | Some concerns |

CHO, carbohydrate; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; GI, glycemic index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAFLD, non-alcoholic fatty liver disease; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; RCT, randomized controlled trial; SFA, saturated fatty acids.
In the RCT by Dinu et al. (Kamut Khorasan vs. Modern Wheat) (20), there were tendencies toward reductions in total (from 5.89 ± 1.0 to 5.39 ± 0.94 vs. from 5.51 ± 0.65 to 5.56 ± 0.73 mmol/L, P = 0.096) and LDL cholesterol (from 3.76 ± 0.94 to 3.46 ± 0.85 vs. from 3.36 ± 1.1 to 3.37 ± 0.92 mmol/L, P = 0.12), and in triglycerides (from 1.57 ± 0.97 to 1.36 ± 0.51 vs. from 1.41 ± 0.56 to 1.50 ± 0.57 mmol/L, P = 0.16), in the kamut vs. modern wheat group. There was no clear effect on HDL cholesterol (from 1.43 ± 0.33 to 1.39 ± 0.35 vs. from 1.45 ± 0.44 to 1.37 ± 0.35 mmol/L, P = 0.99). The evidence was considered as Very low for all outcomes.

**Kamut Khorasan vs. Modern Wheat**

In the RCT by Dinu et al. (42), there were tendencies toward reductions in total (from 5.89 ± 1.0 to 5.39 ± 0.94 vs. from 5.51 ± 0.65 to 5.56 ± 0.73 mmol/L, P = 0.096) and LDL cholesterol (from 3.76 ± 0.94 to 3.46 ± 0.85 vs. from 3.36 ± 1.1 to 3.37 ± 0.92 mmol/L, P = 0.12), and in triglycerides (from 1.57 ± 0.97 to 1.36 ± 0.51 vs. from 1.41 ± 0.56 to 1.50 ± 0.57 mmol/L, P = 0.16), in the kamut vs. modern wheat group. There was no clear effect on HDL cholesterol (from 1.43 ± 0.33 to 1.39 ± 0.35 vs. from 1.45 ± 0.44 to 1.37 ± 0.35 mmol/L, P = 0.99). The evidence was considered as Very low for all outcomes.

**Olive Oil Enriched With n-3 PUFA vs. Olive Oil**

In the RCT by Sofi et al. (15), there was an increase in HDL cholesterol (from 1.15 ± 0.14 to 1.56 ± 0.24 vs. from 1.13 ± 0.12 to 1.07 ± 0.05 mmol/L, P = 0.03) and a reduction in triglycerides (from 1.86 ± 0.97 to 1.50 ± 0.72 vs. from 1.61 ± 0.28 to 1.84 ± 0.34 mmol/L, P = 0.04) in the enriched vs. regular olive oil group. No clear differences were seen for total (from 5.53 ± 0.72 to 5.51 ± 0.60 vs. from 5.11 ± 0.57 to 4.99 ± 0.58 mmol/L, P = 0.9) or LDL cholesterol (from 3.40 ± 0.64 to 3.45 ± 0.84 vs. from 3.24 ± 0.50 to 3.08 ± 0.60 mmol/L, P = 0.2). The evidence was considered as Very low for all outcomes.

---

**TABLE 3 | Excluded six systematic reviews and 15 RCTs, with reasons.**

| Study type          | Food/comparison                                      | References                                      | Reason for exclusion                           |
|---------------------|------------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Systematic review   | Fructose                                             | Sievenpiper et al. (21)                        | Nutrient, not food-specific                    |
| Systematic review   | Probiotics                                           | Lirussi et al. (22)                            | No RCTs identified                             |
| Systematic review   | Probiotics                                           | Liu et al. (23)                                | Supplements, not foods                         |
| Systematic review   | Probiotics                                           | Ma et al. (24)                                 | Supplements, not foods                         |
| Systematic review   | Probiotics                                           | Xiao et al. (25)                               | Supplements, not foods                         |
| Systematic review   | Probiotics, prebiotics, or synbiotics                | Loman et al. (26)                              | Supplements, not foods                         |
| RCT                 | Alternate-day fasting vs. time-restricted feeding    | Cai et al. (27)                                | Eating patterns, not foods or dietary patterns |
| RCT                 | Bilfabacterium longum with fructo-oligosaccharides   | Malaguernara et al. (28)                       | Supplement, not food                           |
| RCT                 | Catechin-enriched green and oolong tea               | Venkatakrishnan et al. (29)                    | Wrong study population (not NAFLD)             |
| RCT                 | Combined nutraceutical containing berberine,         | Cicero et al. (30)                             | Supplement, not food                           |
| RCT                 | Low-Gl Mediterranean diet                            | Jin et al. (31)                                | Wrong study population (not adults)            |
| RCT                 | Low-carbohydrate vs. low-fat diet                    | Misciagna et al. (32)                          | Data not provided on blood lipids              |
| RCT                 | Low-carbohydrate vs. low-fat diet                    | Jang et al. (33)                               | Data not provided on food intake; and intentional weight loss |
| RCT                 | Low-fat/low-saturated fat/low-Gl diet vs.            | Rodriguez-Hernández et al. (34)                | Aiming for weight loss                         |
| RCT                 | Mediterranean diet vs. Mediterranean lifestyle       | Utzschneider et al. (35)                       | Wrong study population (not NAFLD)             |
| RCT                 | Milk- and soya-phospholipids                         | Katsagoni et al. (36)                          | Aiming for weight loss                         |
| RCT                 | Northern berries                                     | Weiland et al. (37)                            | Supplements, not foods; and no information on NAFLD status |
| RCT                 | Probiotic yogurt                                     | Lehtonen et al. (38)                           | No information on NAFLD status                |
| RCT                 | Sugar                                                | Nabavi et al. (39)                             | Not written in English                         |
| RCT                 | Whole-grain wheat vs. refined wheat                  | Umpleby et al. (40)                            | Different doses only, no comparison food       |

GI, glycemic index; NAFLD, non-alcoholic fatty liver disease; RCT, randomized controlled trial.
In the RCT by Khavasi et al. (16), there were no clear effects on total (from 4.95 ± 1.2 to 4.75 ± 1.2 vs. from 4.31 ± 0.96 to 3.94 ± 0.93 mmol/L, \( P = 0.09 \)), LDL (from 2.90 ± 0.93 to 2.67 ± 0.73 vs. from 2.00 ± 1.2 to 1.68 ± 1.1 mmol/L, \( P = 0.03 \)), or HDL cholesterol (from 0.99 ± 0.21 to 1.01 ± 0.22 vs. from 1.14 ± 0.13 to 1.14 ± 0.16 mmol/L, \( P = 0.3 \)), or on triglycerides (from 2.14 ± 0.63 to 2.15 ± 0.90 vs. from 2.54 ± 1.0 to 2.44 ± 1.1 mmol/L, \( P = 0.053 \)). Some data on variances were estimated because of implausible data in table. The evidence was considered as Very low for all outcomes.

In this RCT, the synbiotic supplement (fructo-oligosaccharides plus \( B. \) animalis) on liver fat content and liver fibrosis in NAFLD was published during the writing of this manuscript (43). This study showed that this synbiotic combination altered the fecal microbiome but had no effect on liver fat, fibrosis, or plasma lipoproteins compared to prebiotic

**DISCUSSION**

In this systematic review of the effects of foods on blood lipids in individuals with NAFLD, no systematic reviews and only 11 RCTs fulfilled the inclusion criteria. No foods or dietary patterns modify blood lipids with High quality evidence in NAFLD. With Moderate evidence, a Healthy dietary pattern reduces fasting triglycerides, compared with standard care. Also with Moderate evidence, a probiotic yogurt, enriched with \( Lactobacillus \) acidophilus La5 and \( Bifidobacterium \) lactis Bb12, decreases total cholesterol, compared with conventional yogurt, and with Low evidence, reduces LDL cholesterol and triglycerides. Also with Low evidence, a synbiotic yogurt containing \( Bifidobacterium \) animalis and inulin reduces total and LDL cholesterol, and triglycerides. Finally, with Low evidence, a Mediterranean dietary pattern (high in unsaturated fatty acids) reduces total cholesterol (but not other lipoproteins) compared with a Low-fat dietary pattern. For all other comparisons, the evidence quality was considered as Very low for all effects, or lack thereof.

The limited number of studies discovered was somewhat surprising, given the prevalence and clinical significance of NAFLD. One plausible reason may be that, in most studies on diet and CVD risk factors, liver fat content is not easily attainable and thus overlooked. Also, many patients with NAFLD go undiagnosed, as it usually presents with little symptoms. The effect of dietary fat type (e.g., saturated/polyunsaturated fat) on plasma lipoproteins is diminished in individuals with obesity compared with normal body weight (5). Considering the strong association between NAFLD and obesity, it can thus be speculated that the effect of dietary fat type may be less effective in individuals with compared to without NAFLD (due to concomitant overweight), however this requires further investigation. Factors proposed to blunt the effectiveness of dietary fat modification on LDL cholesterol in obesity (and thus speculatively in NAFLD) are increased inflammation, insulin resistance, and endogenous cholesterol synthesis (6).

An RCT testing the effects of a synbiotic supplement (fructo-oligosaccharides plus \( B. \) animalis) on liver fat content and liver fibrosis in NAFLD was published during the writing of this manuscript (43). This study showed that this synbiotic combination altered the fecal microbiome but had no effect on liver fat, fibrosis, or plasma lipoproteins compared to prebiotic
### TABLE 4 | GRADE table of the effects of dietary patterns and foods on blood lipids in NAFLD.

| Food/comparison | Type and no. of studies | Outcome                                  | Effect     | GRADE evidence |
|-----------------|-------------------------|------------------------------------------|------------|----------------|
| Healthy dietary pattern vs. usual care | 1 RCT (10) | Total cholesterol | Reduction | Very low (⊕) |
|                  |                         | LDL cholesterol                          | Reduction  | Very low (⊕)   |
|                  |                         | HDL cholesterol                          | No clear effect | Very low (⊕) |
|                  |                         | Triglycerides                            | Reduction  | Moderate (⊕ ⊕) |
| Mediterranean diet vs. Low-fat diet | 1 RCT (19) | Total cholesterol | Reduction | Very low (⊕) |
|                  | 2 RCTs (19, 20) | LDL cholesterol                          | No clear effect | Low (⊕) |
|                  |                         | HDL cholesterol                          | No clear effect | Low (⊕) |
|                  |                         | Triglycerides                            | No clear effect | Low (⊕) |
| MUFA diet vs. High CHO/High-fiber/Low-GI diet | 1 RCT (12, 13) | TC                                       | Reduction  | Very low (⊕ ⊕) |
|                  |                         | LDL cholesterol                          | No clear effect | Low (⊕) |
|                  |                         | HDL cholesterol                          | No clear effect | Low (⊕) |
|                  |                         | Triglycerides                            | No clear effect | Low (⊕) |
| Artifically sweetened beverages vs. sugar-sweetened beverages | 1 RCT (14) | Total cholesterol | No clear effect | Very low (⊕) |
|                  |                         | HDL cholesterol                          | No clear effect | Very low (⊕) |
|                  |                         | Triglycerides                            | Increase   | Very low (⊕) |
| Kamut khorasan vs. modern wheat | 1 RCT (42) | Total cholesterol | Reduction  | Very low (⊕) |
|                  |                         | LDL cholesterol                          | Reduction  | Very low (⊕) |
|                  |                         | HDL cholesterol                          | No clear effect | Very low (⊕) |
| Olive oil vs. canola oil | 1 RCT (18) | HDL cholesterol                          | Increase   | Very low (⊕) |
|                  |                         | Triglycerides                            | No clear effect | Very low (⊕) |
| Olive oil vs. commonly used oil (soybean/safflower) | 1 RCT (18) | Total cholesterol | Reduction  | Very low (⊕) |
|                  |                         | HDL cholesterol                          | No clear effect | Very low (⊕) |
|                  |                         | Triglycerides                            | Increase   | Very low (⊕) |
| Canola oil vs. commonly used oil (soybean/safflower) | 1 RCT (18) | Total cholesterol | Reduction  | Very low (⊕) |
|                  |                         | HDL cholesterol                          | No clear effect | Very low (⊕) |
| Olive oil enriched with n-3 PUFA vs. olive oil | 1 RCT (15) | Total cholesterol | Reduction  | Very low (⊕) |
| Pickled caper fruit vs. control (background) diet | 1 RCT (16) | Total cholesterol | Reduction  | Very low (⊕) |
|                  |                         | LDL cholesterol                          | No clear effect | Very low (⊕) |
|                  |                         | HDL cholesterol                          | No clear effect | Very low (⊕) |
|                  |                         | Triglycerides                            | Reduction  | Moderate (⊕ ⊕) |
| Probiotic yogurt (enriched with L. acidophilus La5 and B. lactis Bb12) vs. conventional yogurt (L. bulgaricus and Streptococcus thermophilus) | 1 RCT (17) | Total cholesterol | Reduction  | Low (⊕) |
|                  |                         | LDL cholesterol                          | No clear effect | Low (⊕) |
|                  |                         | HDL cholesterol                          | No clear effect | Low (⊕) |
|                  |                         | Triglycerides                            | Reduction  | Low (⊕) |

(Continued)
TABLE 4 | Continued

| Synbiotic yogurt (B. animalis and inulin) vs. conventional yogurt | 1 RCT (11) | Total cholesterol | Reduction | Low (⊕⊕)\textsuperscript{a,b,d,e} |
| Synbiotic yogurt (B. animalis and inulin) vs. control | 1 RCT (11) | Total cholesterol | Reduction | Low (⊕⊕)\textsuperscript{a,b,d,e} |
| Conventional yogurt (Streptococcus thermophilus and L. delbrueckii subsp. Bulgaricus) vs. control | 1 RCT (11) | Total cholesterol | Reduction | Low (⊕⊕)\textsuperscript{a,b,d,e} |
| CHO, carbohydrate; GI, glycemic index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAFLD, non-alcoholic fatty liver disease; MUFA, monounsaturated fatty acids; RCT, randomized controlled trial. Downgraded for \textsuperscript{a}Risk of bias, \textsuperscript{b}Inconsistency, \textsuperscript{c}Indirectness, \textsuperscript{d}Imprecision, or upgraded for \textsuperscript{e}Large effects.

**FIGURE 3** | Meta-analysis of Mediterranean vs. Low fat dietary pattern for blood lipids in NAFLD. (A) Forest plot for the effects on HDL Cholesterol. (B) Forest plot for the effects on Triglycerides. Ryan et al. (20) is a cross-over study and its variance has been adjusted accordingly, in order to increase its weighting.

The present systematic review has limitations. Studies on dietary supplements and individual nutrients were not included in our searches, which could have been relevant e.g., for determining which bacterial strains (in probiotics) may provide beneficial effects on plasma lipoproteins. Also, we did not search gray literature or contact authors for additional information, and only studies published in English were included. Thus, we cannot rule out that additional relevant studies may exist. In addition, the present study could not confidently determine effect sizes or required daily doses for the included foods, because of the scarce data available.

**CONCLUSIONS**

The results from the included RCTs are mostly in line with current guidelines for the treatment of dyslipidemia or prevention of CVD (7, 44) in other populations. However, it is not possible from the present data to determine which foods significantly modify blood lipids in NAFLD. The possible
beneficial effect of probiotics enriched with certain bacterial strains on plasma lipoproteins warrants further study.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

REFERENCES

1. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nature reviews gastroenterology & hepatology. (2017) 14:32–42. doi: 10.1038/nrgastro.2016.147
2. Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. (2016) 65:1109–23. doi: 10.1016/j.metabol.2016.05.003
3. Stok-Goñalves D, Hovingh GK, Niewoehner D, Holleboom AG. NAFLD and atherosclerosis: two sides of the same dysmetabolic coin? Trends Endocrinol Metab. (2019) 30:891–902. doi: 10.1016/j.tem.2019.08.008
4. Kendall CW, Jenkins DJ. A dietary portfolio: maximal reduction of low-density lipoprotein cholesterol with diet. Curr Atheroscler Rep. (2004) 6:492–8. doi: 10.1007/s11883-004-0091-9
5. Sundsfjord TM, Svendsen M, Heggen E, Dushanov S, Klemsdal TO, Tonstad S. BMI modifies the effect of dietary fat on atherogenic lipids: a randomized clinical trial. Am J Clin Nutr. (2019) 110:832–41. doi: 10.1093/ajcn/nqz113
6. Flock MR, Green MH, Kris-Etherton PM. Effects of adiposity on plasma lipid response to reductions in saturated fatty acids and cholesterol. Adv Nutr. (2011) 2:261–74. doi: 10.3945/an.111.004222
7. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. (2020) 41:111–88. doi: 10.1093/eurheartj/ehz297
8. Vors C, Le Barz M, Bourliou C, Michalski MC. Dietary lipids and cardiometabolic health: a new vision of structure-activity relationship. Curr Opin Clin Nutr Metab. Care. (2020) 23:451–9. doi: 10.1097/MOC.0000000000001087
9. Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (Updated September 2020). (2020). Available online at: http://www.training.cochrane.org/handbook (accessed October 1, 2020).
10. Arab A, Hadri A, Moosavin SP, Rafie N, Hajianfar H. The effect of nutrition education program on overweight/obese patients with non-alcoholic fatty liver disease: a single-blind randomized controlled trial. Clin Nutr Res. (2019) 8:238–46. doi: 10.7762/cnr.2019.8.3.238
11. Bakhshimoghaddam F, Shateri K, Sina M, Hashemian M, Alizadeh M. Daily consumption of syrabi yogurt decreases liver steatosis in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Int J Food Sci Nutr. (2019) 70:202–11. doi: 10.1080/09637486.2019.1640051
12. Boffetta L, Prinster A, Annuzzi G, Costagliola L, Mangione A, Vitelli A, et al. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

The study was conceptualized by DI. AR and FR performed screening. AR, FR, and DI performed data extraction. Risk of bias was assessed by FR and DI. Data analysis and grading of the evidence was performed by DI, with support from AR and FR. The paper was written by AR, FR, and DI. All authors contributed to the article and approved the submitted version.
31. Jin R, Welsh JA, Le NA, Holzberg J, Sharma P, Martin DR, et al. Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. *Nutrients*. (2014) 6:3187–201. doi: 10.3390/nu6083187

32. Misciagna G, Del Pilar Diaz M, Caramia DV, Bonsfiglio C, Franco I, Noviello MR, et al. Effect of a low glycemic index Mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinical trial. *J Nutr Health Aging*. (2017) 21:404–12. doi: 10.1007/s12603-016-0809-8

33. Jang EC, Jun DW, Lee SM, Cho YK, Ahn SB. Comparison of efficacy of low-carbohydrate and low-fat diet education programs in non-alcoholic fatty liver disease: a randomized controlled study. *Hepatol Res*. (2018) 48:E22–29. doi: 10.1111/hepr.12918

34. Rodríguez-Hernández H, Cervantes-Huerta M, Rodríguez-Moran M, Guerrero-Romero F. Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet. *Ann Hepatol*. (2011) 10:486–92. doi: 10.1016/S1665-2681(19)31517-0

35. Utzschneider KM, Bayer-Carter JL, Arbuckle MD, Tidwell JM, Richards TL, Craft S. Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects. *Br J Nutr*. (2013) 109:1096–104. doi: 10.1017/S0007114512002966

36. Katsagoni CN, Papatheodoridis GV, Ioannidou P, Deutsch M, Alexopoulou A, Papadopoulos N, et al. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. *Br J Nutr*. (2018) 120:164–75. doi: 10.1017/S000711451800137X

37. Weiland A, Bub A, Barth SW, Schrezenmeir J, Pfeuffer M. Effects of dietary milk- and soya-phospholipids on lipid-parameters and other risk indicators for cardiovascular diseases in overweight or obese men-two double-blind, randomised, controlled, clinical trials. *J Nutr Sci*. (2016) 5:e21. doi: 10.1017/jns.2016.9

38. Lehtonen HM, Suomela JP, Tahvonen R, Vaarno J, Venojarvi M, Viihki J, et al. Berry meals and risk factors associated with metabolic syndrome. *Eur J Clin Nutr*. (2010) 64:614–21. doi: 10.1038/ejcn.2010.27

39. Nabavi S, Rafraf M, Somi M H, Homayouni-Rad A, Asghari-jafarabadi M. The effects of probiotic yogurt on metabolic factors in nonalcoholic fatty liver disease. *SJKU*. (2018) 26:12–25. doi: 10.22102/20.6.12

40. Umpleby AM, Shojaee-Moradie F, Fielding B, Li X, Marino A, Alsini N, et al. Impact of liver fat on the differential partitioning of hepatic triacylglycerol into VLDL subclasses on high and low sugar diets. *Clin Sci*. (2017) 131:2561–73. doi: 10.1042/CS20171208

41. Schutte S, Esser D, Hoevenaars FPM, Hooiveld GJEJ, Priebe MG, Vonk RJ, et al. A 12-wk whole-grain wheat intervention protects against hepatic fat: the Graandoos study, a randomized trial in overweight subjects. *Am J Clin Nutr*. (2018) 108:1264–74. doi: 10.1093/ajcn/nqy204

42. Dinu M, Whittaker A, Pagliai G, Giangrandi I, Colombini B, Gori AM, et al. A khorasan wheat-based replacement diet improves risk profile of patients with nonalcoholic fatty liver disease (NAFLD): a randomized clinical trial. *J Am Coll Nutr*. (2018) 37:508–14. doi: 10.1080/07315724.2018.1445047

43. Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alkhathary A, et al. Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. *Gastroenterology*. (2020) 158:1597–610.e7. doi: 10.1053/j.gastro.2020.01.031

44. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. *Circulation*. (2019) 140:e596–646. doi: 10.1161/CIR.0000000000000725

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Rosqvist, Rydell and Iggman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.